Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Taito Fukushima(Kanagawa Prefectural Hospital Organization), Shin Maeda(University of Tokyo Hospital), Hisashi Hidaka(Kitasato University), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Yoshitaka Arase(Tokai University), Chika Kusano(Kitasato University), Haruki Uojima(Kitasato University), Kota Tsuruya(Tokai University), Tatehiro Kagawa(Tokai University), Nobuhiro Hattori(St. Marianna University School of Medicine), Tsunamasa Watanabe(St. Marianna University School of Medicine), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Katsuaki Tanaka(Yokohama City University Medical Center), Hiroki Ikeda(St. Marianna University School of Medicine), Makoto Ueno(Kanagawa Prefectural Hospital Organization)
Cited by 42
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
|Journal of Biological Chemistry|1990|625
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, a calmodulin antagonist, inhibits cell proliferation.
|Proceedings of the National Academy of Sciences|1981|586
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573